Study of Crizotinib for ROS1 and MET Activated Lung Cancer

NCT04084717 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

50

Enrollment

OTHER

Sponsor class

Conditions

Non-squamous Non-small-cell Lung Cancer
Stage IV Non-small Cell Lung Cancer
ROS1 Gene Rearrangement
MET Activating Mutation
MET Amplification

Interventions

DRUG: Crizotinib

Sponsor

University Health Network, Toronto

Collaborators

[object Object]